Literature DB >> 3924141

Modulation of thrombin-mediated activation of factor VIII:C by calcium ions, phospholipid, and platelets.

M B Hultin.   

Abstract

The activation of factor VIII:C by thrombin appears to be an important prerequisite for the function of factor VIII:C as a cofactor in factor X activation in coagulation. The possible modulation of factor VIII:C activation by potential cofactors such as calcium ions, phospholipid, and platelets was studied systematically. Factor VIII:C activation could not be studied in the complete absence of Ca2+, since factor VIII:C activity decayed rapidly in calcium-free buffers, EDTA, or ethylene glycol tetra-acetic acid (EGTA), with only partial or no recovery of activity after readdition of Ca2+, Mn2+, or Mg2+. Added calcium chloride at 1.25, 2.5, 4, 10, 50, and 200 mmol/L produced progressive inhibition of factor VIII:C activation, with complete inhibition achieved by 50 mmol/L. Crude phospholipid preparations gave varying results, while purified phospholipids either had no effect or inhibited activation. This paper reports the new finding that fresh washed human platelets markedly potentiated factor VIII:C activation by a low concentration of thrombin (0.02 U/mL), even with prostaglandin E1 (PGE1) or dibutyryl cyclic AMP (cAMP) added to the washed platelets. However, the activity of platelets in factor VIII:C activation was inhibited by inclusion of PGE1 or dibutyryl cAMP during platelet washing, and ionophore A23187 increased this platelet activity; these data suggest that platelet stimulation is involved in the development of this activity. When platelets were maximally stimulated by thrombin (0.5 U/mL), the external calcium concentration increased 55 to 160 mumol/L, as measured with murexide, supporting the possible modulation of factor VIII:C activation by a transient increase in Ca2+ at the platelet surface.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924141

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  First determination of the secondary structure of purified factor VIII light chain.

Authors:  N Bihoreau; M P Fontaine-Aupart; A Lehegarat; M Desmadril; J M Yon
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

2.  Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

Authors:  J C Reverter; S Béguin; H Kessels; R Kumar; H C Hemker; B S Coller
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  Intraarterially administered abciximab as an adjuvant thrombolytic therapy: report of three cases.

Authors:  O-Ki Kwon; Ki Jae Lee; Moon Hee Han; Chang-Wan Oh; Dae Hee Han; Young Cho Koh
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

Review 4.  Oral factor Xa inhibitors for the long-term management of ACS.

Authors:  James W Wisler; Richard C Becker
Journal:  Nat Rev Cardiol       Date:  2012-02-21       Impact factor: 32.419

5.  Effect of perturbation of specific folate receptors during in vitro erythropoiesis.

Authors:  A C Antony; E Bruno; R A Briddell; J E Brandt; R S Verma; R Hoffman
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

6.  The association of human coagulation factors VIII, IXa and X with phospholipid vesicles involves both electrostatic and hydrophobic interactions.

Authors:  J S Atkins; P R Ganz
Journal:  Mol Cell Biochem       Date:  1992-05-13       Impact factor: 3.396

Review 7.  Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders.

Authors:  Houssam Al-Koussa; Ibrahim AlZaim; Marwan E El-Sabban
Journal:  J Clin Med       Date:  2022-08-22       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.